Hedera Dx is dedicated to making liquid biopsies globally accessible for patients with cancer. Their solution radically streamlines tumor profiling and cancer treatment monitoring by enabling hospital laboratories to perform CE-IVDR compliant and clinically actionable liquid biopsies in-house.

Liquid biopsies analyze circulating tumor DNA (ctDNA) from a simple blood draw, providing personalized patient journeys and improved treatment options for many patients.

Hedera Dx envisions transforming oncology by providing better therapy options for more patients through easy adoption of NGS-based liquid biopsies within hospital laboratories. Their solution aims to overcome challenges such as assay validation, regulatory compliance, and clinical trial scarcity to make liquid biopsy testing broadly feasible and effective.

The company supports clinical evidence development and works on decentralizing molecular testing to provide faster, simpler, and more insightful cancer care.